These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 25483677)

  • 1. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
    Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
    Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
    Wurz GT; Gutierrez AM; Greenberg BE; Vang DP; Griffey SM; Kao CJ; Wolf M; DeGregorio MW
    J Transl Med; 2013 Mar; 11():64. PubMed ID: 23496860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
    Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
    Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
    Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.
    Mitchell P; Thatcher N; Socinski MA; Wasilewska-Tesluk E; Horwood K; Szczesna A; Martín C; Ragulin Y; Zukin M; Helwig C; Falk M; Butts C; Shepherd FA
    Ann Oncol; 2015 Jun; 26(6):1134-1142. PubMed ID: 25722382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
    Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
    Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
    Kao CJ; Wurz GT; Monjazeb AM; Vang DP; Cadman TB; Griffey SM; Wolf M; DeGregorio MW
    Cancer Immunol Res; 2014 Jun; 2(6):581-9. PubMed ID: 24894093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
    Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
    J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
    Hong S; Qian J; Li H; Yang J; Lu Y; Zheng Y; Yi Q
    Cancer Immunol Immunother; 2012 Apr; 61(4):561-71. PubMed ID: 22002243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
    Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
    Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
    Ocadlíková D; Kovárová L; Hájek R; Michálek J
    Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
    Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M;
    Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.